XOMAXOMA Corp

Nasdaq xoma.com


$ 25.33 $ 0.24 (0.97 %)    

Monday, 06-May-2024 15:59:49 EDT
QQQ $ 439.97 $ 4.77 (1.1 %)
DIA $ 388.40 $ 1.68 (0.43 %)
SPY $ 516.34 $ 5.28 (1.03 %)
TLT $ 90.16 $ 0.35 (0.39 %)
GLD $ 215.21 $ 2.24 (1.05 %)
$ 25.02
$ 25.22
$ 0.00 x 0
$ 0.00 x 0
$ 25.00 - $ 25.33
$ 13.48 - $ 27.00
5,879
na
287M
$ 0.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-08-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-09-2023 03-31-2023 10-Q
5 03-09-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-04-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 03-08-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-10-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-05-2020 03-31-2020 10-Q
17 03-10-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-06-2019 03-31-2019 10-Q
21 03-07-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-09-2018 03-31-2018 10-Q
25 03-07-2018 12-31-2017 10-K
26 11-06-2017 09-30-2017 10-Q
27 08-08-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 03-16-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-03-2016 06-30-2016 10-Q
32 05-04-2016 03-31-2016 10-Q
33 03-09-2016 12-31-2015 10-K
34 11-06-2015 09-30-2015 10-Q
35 08-10-2015 06-30-2015 10-Q
36 05-07-2015 03-31-2015 10-Q
37 03-11-2015 12-31-2014 10-K
38 11-06-2014 09-30-2014 10-Q
39 08-07-2014 06-30-2014 10-Q
40 05-07-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

Core News & Articles

Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOM...

 leerink-partners-initiates-coverage-on-xoma-with-outperform-rating-announces-price-target-of-40

Leerink Partners analyst Jason Zhuang initiates coverage on XOMA (NASDAQ:XOMA) with a Outperform rating and announces Price ...

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

Core News & Articles

As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered ...

 hc-wainwright--co-maintains-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis maintains XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

 recap-xoma-q4-earnings
Recap: XOMA Q4 Earnings
03/08/2024 12:40:05

 xoma-fy-gaap-eps-404-may-not-be-comparable-to-205-estimate-sales-476m-miss-650m-estimate

XOMA (NASDAQ:XOMA) reported quarterly losses of $(4.04) per share which missed the analyst consensus estimate of $(2.05) by 97....

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

 biotech-royalty-aggregator-xoma-to-acquire-small-cancer-drug-developer-kinnate-biopharma

XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in ...

Core News & Articles

The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niya...

 xoma-expands-its-commercial-royalty-and-milestone-portfolio-with-dsuvia-acquisition-provided-an-8m-non-dilutive-royalty-capital-solution-to-talphera

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial...

 xoma-to-make-1m-milestone-payment-to-ladrx-reveals-fda-acceptance-of-zevras-arimoclomol-nda-filing-for-niemann-pick-disease-type-c

In June 2023, XOMA announced it had paid LadRx a $5 million upfront payment plus a share of future event-based milestones to ac...

 xoma-names-owen-hughes-as-ceo-and-jack-wyszomierski-as-chairman-of-board

Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023.

 hc-wainwright--co-reiterates-buy-on-xoma-maintains-74-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION